Navigation Links
Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
Date:2/16/2011

or the treatment of genetically defined sub-populations of patients with Parkinson's disease and Alzheimer's disease.  Amicus previously reported encouraging results from preclinical studies evaluating the use of a pharmacological chaperone for the treatment of Parkinson's disease.  Amicus will present additional data from preclinical studies that evaluated the pharmacological chaperone AT2101 in mouse models of Parkinson's disease as well as data related to the properties of new compounds, including AT3375.  In 2011, the Company expects to complete late-stage preclinical proof of concept studies, including IND-enabling activities, for AT3375.  The Amicus Parkinson's Disease program is funded in part by a grant from The Michael J. Fox Foundation (MJFF).

Additionally, Amicus continues to advance its preclinical program evaluating a pharmacological chaperone approach for the treatment of Alzheimer's disease.  The Company will present scientific data on the link between lysosomal dysfunction and neurodegeneration, including data related to a preclinical program evaluating a pharmacological chaperone approach for the treatment of Alzheimer's disease.   The Company expects to continue preclinical proof of concept studies during 2011.  The Amicus Alzheimer's Disease program is funded in part by a grant from the Alzheimer's Drug Discovery Foundation (ADDF).About AmigalOn October 29, 2010, Amicus announced a definitive agreement with GlaxoSmithKline PLC (GSK) to develop and commercialize Amigal (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease as a monotherapy. Under the terms of the agreement, GSK received an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl. GSK and Amicus are also investigating Amigal as a treatment for Fabry disease when co-administered with ERT and have commenced a Phase 2 study as noted above.  

The Phase 3 study (Study 011) of migalastat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
10. Amicus Therapeutics Announces Change to Board of Directors
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR ... December 22, 2014, thereby completing the U.S. HSR ... acquisition of the Company by Merck KGaA, Darmstadt, ... another condition to closing the transaction, which remains ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... 22 Here are today,s highlights from the AACE Annual Meeting & Clinical Congress ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b ) , ... Research Shows First-of-Its-Kind Hydrogel Decreases Obese Patients, Desire for Food ... New research indicates that a first-of-its-kind, superabsorbent hydrogel ...
... ... Universities to Qualify for Free Oragene®•DNA Collection Kits for Classroom Use , ... Ottawa, ON (PRWEB) April 22, ... collection, stabilization and preparation, today announced it is marking DNA Day 2010 by introducing ...
... ... , ... April 22, 2010 -- Therapeutic Proteins Inc. (TPI) today announced the completion ... meet U.S. Food and Drug Administration (FDA) requirements. The Chicago facility is located at ...
Cached Biology Technology:Thursday News Highlights from the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress 2Thursday News Highlights from the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress 3DNA Genotek Marks DNA Day 2010 with a Focus on Supporting Science Education 2DNA Genotek Marks DNA Day 2010 with a Focus on Supporting Science Education 3Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 2Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 3Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 4
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... of 11 research centers in China are reporting for the ... the proteins produced by genes in a single human organ. ... both protein and transcript levels could become a roadmap for ... include hepatitis and liver cancer, which is at epidemic levels ...
... of altruism has long been debated in philosophical circles, ... From the perspective of natural selection, altruism may ... of a relative,s survival and reproduction increases the chance ... behavior, kin recognition, and altruism are well known in ...
... Conn. -- Amphibians, for years considered a leading indicator ... according to a meta-analysis to be published in ... 28,000 toxicological tests, researchers from the University of South ... the prevailing view that amphibians, with their permeable skin ...
Cached Biology News:Can a plant be altruistic? 2Amphibians as environmental omen disputed 2
... contain 60 rabbit tissue samples arrayed on Superfrost ... slides and 1 hematoxylin and eosin (H&E) stained ... different tissues from 4 rabbit organisms, for a ... tissue sample (or core) is 1.5 mm in ...
... a wide variety of purity levels, scales and ... Purity: IG(>50%), >70%, >80% and >95% ... Length: Up to 120 residues ... acids, MAPs, KLH/BSA conjugation, and much more. ...
... Antigen sequence: H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH ... For our corresponding peptide ... 2 5 I-labelled ... (human) (H-1470) and ([ ...
... you to identify over 150 peptide ... protein isoforms, protein subsets, and suppress ... peptide-protein associations and relationships easily. The ... and relative protein expression analysis for ...
Biology Products: